Key facts
- It has raised $15.5M; the latest was Secondary Transaction - Private in Dec 2025.
- Notable investors include Fortune Link Fund Management, Huahe Capital, Jiangyin New Guolian Venture Capital, Kaiwu Capital, Share Venture.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Beita PharmaTech
- ·The full record, as it builds
Funding rounds
No funding rounds for Beita PharmaTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beita PharmaTech
Developer of isotope-labeled precursor compounds to support ADME, clinical, environmental, diagnostic research, and nuclear energy applications. The company's products are mainly used to label small pharmaceutical molecules or biologically active small molecules, which are used in pharmacokinetics, clinical and disease detection research, and provide isotope labeling and customized services, analysis and separation technologies service etc.
- Sector
- Healthcare
- HQ
- Wuxi, China
- Founded
- 2008
- Employees
- 13
- Website
- beitapharmatech.com/
- Ownership
- Privately Held (backing)
Beita PharmaTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beita PharmaTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beita PharmaTech in its N-PORT filings yet. We sweep new filings monthly.